Clinical trials: Oropharynx
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Dysphagia
The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy
This is a prospective, multi-site, randomised, sham-controlled, single-blind (outcome assessor-blinded) study designed to assess the effects of Pharyngeal Electrical Stimulation (PES) (using Phagenyx®) for the treatment of…
- Trial name
- PhINEST (NCT03840395)
- Testing
- Pharyngeal Electrical Stimulation (PES)
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 72 people
- Sponsor
- Phagenesis Ltd.
Candidiasis, Oral, HIV Infections
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
The purpose of this study is to see if it is safe and effective to give L-743,872 to patients with thrush, an AIDS-related yeast infection of the mouth, that has not been cured with fluconazole treatment.
- Trial name
- NCT00005920
- Testing
- L-743,872
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Dysphagia, Stroke
Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia
The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.
- Trial name
- NCT02522351
- Testing
- Cereal extract concentration 1, Cereal extract concentration 2, Cereal extract concentration 3
- Where
- 2 sites in Belgium, France
- Volunteers
- 35 people
- Sponsor
- Société des Produits Nestlé (SPN)
Pulmonary Disease, Chronic Obstructive, Asthma
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the…
- Trial name
- NCT00153075
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Candidiasis, Oral, HIV Infections
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
- Trial name
- NCT00002399
- Testing
- Posaconazole, Fluconazole
- Where
- 53 sites in United States, Argentina and 16 more
- Volunteers
- 500 people
- Sponsor
- Schering-Plough
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
COVID-19
Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19
Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). A double blind clinical trial will be conducted to evaluate the Device against placebo in COVID-19 positive…
- Trial name
- KONS-COVID19 (NCT04357990)
- Testing
- Viruxal Oral and Nasal Spray
- Where
- Iceland
- Volunteers
- 128 people
- Sponsor
- Kerecis Ltd.
Dysphagia
Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia
Assessment of the improvement of the safety of the swallowing function under 3 natural ingredients known to be agonist of sensory receptors.
- Trial name
- NCT02422576
- Testing
- cinnamon extract, lemon extract, lemon extract plus eucalyptus extract
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Société des Produits Nestlé (SPN)
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System.
- Trial name
- NCT06112535
- Testing
- Versius Surgical System
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- CMR Surgical Ltd
Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma
Validity of Viome's Oral/throat Cancer Test
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S.
- Conditions
- Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
- Trial name
- NCT06174428
- Testing
- Oral/Throat cancer test
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viome
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase II Trial of Allovectin-7® for Head and Neck Cancer
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck
- Trial name
- NCT00050388
- Testing
- Allovectin-7®
- Where
- 10 sites in United States
- Sponsor
- Vical
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Advanced Head and Neck Squamous Cell Carcinoma
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab.
- Trial name
- NCT03254927
- Testing
- CDX-3379 and cetuximab
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Celldex Therapeutics
Oropharyngeal Carcinoma (OPC)
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer.
- Trial name
- TEMPO-1 (NCT07768189)
- Testing
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor)
- Where
- 111 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor
- Trial name
- NCT05787535
- Testing
- Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell
- Where
- China
- Volunteers
- 17 people
- Sponsor
- HRYZ Biotech Co.
COVID-19 Respiratory Infection, SARS-CoV2 Infection
Echinaforce COVID-19 Shedding Study
Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness.
- Trial name
- NCT04999098
- Testing
- Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture
- Where
- Bulgaria
- Volunteers
- 40 people
- Sponsor
- A. Vogel AG
Oropharyngeal Candidiasis, Candidemia
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
- Conditions
- Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
- Trial name
- NCT00608335
- Testing
- Micafungin
- Where
- 13 sites in United States, South Africa
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc